Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors

Antivir Chem Chemother. 2014 Jan 29;23(4):145-9. doi: 10.3851/IMP2551.


Persistence of HIV-1 in latently infected CD4(+) T-cells prevents eradication in HIV-infected treated patients. Latency is characterized by a reversible silencing of transcription of integrated HIV-1. Several molecular mechanisms have been described which contribute to latency, including the establishment and maintenance of repressive chromatin on the HIV-1 promoter. Histone deacetylation is a landmark modification associated with transcriptional repression of the HIV-1 promoter and inhibition of histone deacetylase enzymes (HDACs) reactivates latent HIV-1. Here, we review the different HDAC inhibitors that have been studied in HIV-1 latency and their therapeutic potential in reactivating latent HIV-1.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1 / drug effects*
  • HIV-1 / physiology*
  • Histone Deacetylase Inhibitors / pharmacology*
  • Humans
  • Virus Latency / drug effects*


  • Histone Deacetylase Inhibitors